Form 4: Crinetics Pharmaceuticals CFO Tobin Schilke Reports Acquisition of Stock and Options
SEC Form 4 Filing
Tobin Schilke, CFO of Crinetics Pharmaceuticals, reports the acquisition of 52,000 shares of common stock and options to purchase 80,000 shares.
Summary
- On March 10, 2025, Tobin Schilke, the Chief Financial Officer of Crinetics Pharmaceuticals, acquired 52,000 shares of common stock.
- These shares were received as restricted stock units, vesting 25% annually starting March 1, 2026.
- Schilke also acquired options to purchase 80,000 shares of common stock at an exercise price of $33.75.
- These options vest 25% on February 28, 2026, with the remaining shares vesting monthly over the following 36 months, contingent upon continued employment.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of executive compensation. The acquisition of shares and options suggests confidence, but it's a routine event.
Positives
- The acquisition of stock and options by the CFO signals confidence in the company's future performance.
Future Outlook
The vesting schedules for both the restricted stock units and stock options are contingent upon the reporting person's continued employment with the issuer.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's views on the company's prospects.
Comparison to Industry Standards
- Stock option grants and restricted stock units are common forms of executive compensation in the pharmaceutical industry.
- Vesting schedules typically align with industry norms, incentivizing long-term commitment and performance.
- Comparing the size of the grant to those of peer companies such as Neurocrine Biosciences or Ionis Pharmaceuticals would provide further context.
Stakeholder Impact
- The acquisition of shares and options by the CFO can positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Date of transaction: Acquisition of common stock and stock options. |
| 03/11/2025 | Date of Form 4 filing. |
| 02/28/2026 | First vesting date for 25% of the stock options. |
| 03/01/2026 | First vesting date for 25% of the restricted stock units. |
| 03/09/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.